INTRODUCTION:: @entity1 with @entity5 and poor performance status and/or weight loss do not seem to benefit from standard therapy. Based on the preclinical interaction between epidermal growth factor receptor inhibitors and radiation, we designed a trial of induction chemotherapy followed by thoracic radiotherapy and concurrent @entity3866 . METHODS:: @entity1 with poor-risk unresectable @entity5 received two cycles of @entity3003 at an AUC of 5 and nab- @entity1311 at 100 mg/m on days 1 and 8 every 21 days, followed by @entity3866 administered concurrently with thoracic radiotherapy. Maintenance was not permitted. Molecular analysis was performed in available specimens. Seventy-two eligible @entity1 were required to test whether the 1-year survival rate was less than 50% or greater than or equal to 65% with approximately 90% power at a significance level of 0.10. RESULTS:: From March 2008 to October 2011, 78 @entity1 were enrolled, three of whom were ineligible. The median age was 68 (range, 39-88) and 32% were aged greater than or equal to 75 years. @entity1 were evenly distributed between stages IIIA and IIIB and the majority had performance status 2. The overall response rate was 67% and the disease control rate was 93%. Treatment was well tolerated. The median PFS and @entity3012 were 11 and 17 months, respectively. The overall 12-month @entity3012 was 57%, which narrowly missed the prespecified target for significance. CONCLUSIONS:: @entity1 with poor-risk @entity5 had better than expected outcomes with a regimen of induction @entity3003 /nab-paclitaxel followed by thoracic radiotherapy and @entity3866 . However, as per the statistical design, the 12-month @entity3012 was not sufficiently high to warrant further studies.

A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and XXXX in Poor-Risk Stage III Non-Small-Cell Lung Cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG).

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity3012 :: ('MESH:C567932', 'Disease') :: ['OS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['stage III non-small-cell lung cancer'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity3866 :: ('MESH:C400278', 'Chemical') :: ['erlotinib']
@entity3866 :: (MESH:C400278,Chemical) :: ['Erlotinib']
